Daridorexant and Chronic Insomnia: New Real-World Evidence Validated by Sleepacta’s Dormi Algorithm
A new pilot study, recently published in the journal Sleep Medicine, provides significant real-world evidence on the effectiveness of daridorexant for treating chronic insomnia. The research features key contributions from Prof. Ugo Faraguna (President and co-founder of Sleepacta) and a team of multidisciplinary experts.
A distinctive feature of this research is the accuracy of its objective measurements: the actigraphic data were analyzed using Dormi, Sleepacta’s proprietary algorithm. This advanced technology allowed the team to transform sensor recordings into precise and reliable clinical parameters.
Key Findings:
- Reduction in “Sleep Misperception”: Using the Dormi analysis, the study highlighted a significant narrowing of the gap between a patient’s perceived sleep and their actual measured sleep.
- Improved Objective Parameters: The algorithm recorded a statistically significant increase in Total Sleep Time (TST) and Sleep Efficiency (SE) over the three-month treatment period.
- Daytime Benefits: Beyond the objective sleep data, participants reported a marked decrease in pre-sleep cognitive arousal and significant improvements in daytime mood and functioning.
This publication reinforces how the integration of innovative pharmacological therapies and digital monitoring solutions like Dormi is key to a more personalized and evidence-based approach to sleep medicine.
Hoxhaj D, Colitta A, et al. “Real-World Findings of Daridorexant in Chronic Insomnia: A Pilot Study on Subjective and Actigraphic Sleep Parameters”, Sleep Medicine (2026).
